Tissue-specific difference in the molecular mechanisms for the development of acute insulin resistance after injury.
Acute insulin resistance occurs after injury, hemorrhage, infection, and critical illness. However, little is known about the development of this acute insulin-resistant state. In the current study, we found that insulin resistance develops rapidly in skeletal muscle, with the earliest insulin signaling defects at 60 min. However, defects in insulin signaling were measurable even earlier in liver, by as soon as 15 min after hemorrhage. To begin to understand the mechanisms for the development of acute insulin resistance, serine phosphorylation of insulin receptor substrate (IRS)-1 and c-Jun N-terminal kinase phosphorylation/activation was investigated. These markers (and possible contributors) of insulin resistance were increased in the liver after hemorrhage but not measurable in skeletal muscle. Because glucocorticoids are important counterregulatory hormones responsible for glucose homeostasis, a glucocorticoid synthesis inhibitor, metyrapone, and a glucocorticoid receptor antagonist, RU486, were administered to adult rats prior to hemorrhage. In the liver, the defects of insulin signaling after hemorrhage, including reduced tyrosine phosphorylation of the insulin receptor and IRS-1, association between IRS-1 and phosphatidylinositol 3-kinase and serine phosphorylation of Akt in response to insulin were not altered by pretreatment of rats with metyrapone or RU486. In contrast, hemorrhage-induced defects in insulin signaling were dramatically reversed in skeletal muscle, indicating a prevention of insulin resistance in muscle. These results suggest that distinct mechanisms for hemorrhage-induced acute insulin resistance are present in these two tissues and that glucocorticoids are involved in the rapid development of insulin resistance in skeletal muscle, but not in the liver, after hemorrhage.
Li
Li
L
Department of Pathology, Division of Molecular and Cellular Pathology, The University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, Alabama 35294-0019, USA.
Thompson
LaWanda H
LH
Zhao
Ling
L
Messina
Joseph L
JL
D000208:Acute Disease; D000818:Animals; D003345:Corticosterone / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006470:Hemorrhage / Q000150:complications; D006727:Hormone Antagonists / Q000494:pharmacology; D007328:Insulin / Q000502:physiology*; D007333:Insulin Resistance / Q000502:physiology*; D008099:Liver / Q000503:physiopathology; D008297:Male; D008797:Metyrapone / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000503:physiopathology; D010768:Phosphoserine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction; D014947:Wounds and Injuries / Q000150:complications*
D005230:Fatty Acids, Nonesterified; D006727:Hormone Antagonists; D007328:Insulin; D010768:Phosphoserine; D015735:Mifepristone; D003345:Corticosterone; D008797:Metyrapone
Nutr Rev. 1998 Jan;56(1 Pt 2):S170-6
9481140
J Biol Chem. 1997 Oct 3;272(40):25289-95
9312146
Exp Clin Endocrinol Diabetes. 1999;107(2):119-25
10320052
Diabetes Metab. 2004 Sep;30(4):321-6
15525874
Behav Brain Res. 2005 Nov 7;164(2):197-205
16107281
Diabetologia. 2005 Oct;48(10):2119-30
16078016
Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E78-E86
16339925
Annu Rev Physiol. 2006;68:123-58
16460269
J Clin Invest. 2006 Jul;116(7):1793-801
16823477
J Clin Endocrinol Metab. 2006 Oct;91(10):3803-13
16868064
Diabetes. 2006 Nov;55(11):3151-9
17065355
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E654-67
17077342
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1223-30
17179391
Mol Cell Endocrinol. 2007 Sep 15;275(1-2):43-61
17624658
Endocrinology. 2008 May;149(5):2369-82
18187553
J Clin Invest. 1993 May;91(5):2020-30
7683695
J Clin Invest. 1993 Oct;92(4):2065-72
7691892
J Lipid Res. 1994 Sep;35(9):1535-41
7806967
Science. 1996 Feb 2;271(5249):665-8
8571133
J Pediatr Endocrinol Metab. 1999;12 Suppl 3:721-31
10626262
JAMA. 2000 Feb 23;283(8):1038-45
10697064
Pharmacol Rev. 2000 Dec;52(4):513-56
11121509
N Engl J Med. 2001 Nov 8;345(19):1359-67
11794168
J Biol Chem. 2002 Jan 11;277(2):1531-7
11606564
Endocrinology. 2002 Dec;143(12):4820-7
12446609
Nature. 2002 Nov 21;420(6913):333-6
12447443
Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G107-15
12388175
J Biol Chem. 2002 Dec 27;277(52):50230-6
12006582
Am J Manag Care. 2002 Dec;8(20 Suppl):S635-53; quiz S654-7
12510788
Curr Diab Rep. 2001 Oct;1(2):140-7
12643110
J Appl Physiol (1985). 2004 Oct;97(4):1329-37
15155718
Endocrinology. 2004 Nov;145(11):5168-76
15297437
Circ Shock. 1979;6(3):285-95
498433
Diabetes. 1981 Dec;30(12):1000-7
7030826
J Trauma. 1982 Apr;22(4):263-73
6281451
J Clin Endocrinol Metab. 1983 Sep;57(3):529-36
6348064
J Clin Invest. 1983 Nov;72(5):1814-20
6355186
Heart Lung. 1985 Sep;14(5):470-2
3897133
Chest. 1987 Aug;92(2):292-5
3038477
J Endocrinol. 1987 Jun;113(3):473-8
3498000
Intensive Care Med. 1992;18(2):93-6
1613205
Brain Res. 1996 Jun 17;724(2):251-5
8828576
Diabetes. 1997 Jan;46(1):3-10
8971073
Biochem J. 1997 Feb 1;321 ( Pt 3):707-12
9032457
Diabetologia. 1997 Jul;40 Suppl 2:S2-17
9248696
J Clin Endocrinol Metab. 1998 Mar;83(3):757-60
9506721